|Bid||155.18 x 100|
|Ask||155.20 x 100|
|Day's Range||154.79 - 156.13|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||14.72|
|Dividend & Yield||4.60 (3.01%)|
|1y Target Est||N/A|
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
Harpoon Therapeutics Inc. has snared $45 million to develop a prostate cancer therapy that builds on the pioneering immuno-oncology research of co-founder Patrick Baeuerle.